Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological studyUnresolved issues relating to the Shaking Palsy on the celebration of James Parkinson's 250th birthdayMeta-analysis of early nonmotor features and risk factors for Parkinson diseaseThe expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's diseaseCharacterisation of a novel NR4A2 mutation in Parkinson's disease brainHypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's diseaseSecond consensus statement on the diagnosis of multiple system atrophyGlucocerebrosidase mutations in clinical and pathologically proven Parkinson's diseaseHedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapiesAttention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regionsVisual dysfunction in Parkinson's diseaseThe prediagnostic phase of Parkinson's diseaseTDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPTLinked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatmentsStrong association of the Saitohin gene Q7 variant with progressive supranuclear palsyProgressive supranuclear palsy: clinicopathological concepts and diagnostic challengesTransportin1: a marker of FTLD-FUSPunding in Parkinson's disease: its relation to the dopamine dysregulation syndromeMicrodeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disabilityDYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRATesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS StudyThe therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's diseaseCloning of the gene containing mutations that cause PARK8-linked Parkinson's diseaseGeorges Gilles de la Tourette. The man and his timesA common LRRK2 mutation in idiopathic Parkinson's diseaseEncephalitis lethargica. A report of four recent casesThe dopaminergic response in multiple system atrophy.Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's diseaseHallucinations after withdrawal of baclofenDeprenyl in Parkinson's disease"Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's diseaseOscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenylTiapride in levodopa-induced involuntary movementsBromocriptine in parkinsonism. A long-term studyHigh dose naltrexone for dyskinesias induced by levodopaChorea in digoxin toxicity.Levodopa induced chorea in Meige syndrome.Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawalIdazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's diseaseAutonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease
P50
Q22242027-1EA694FF-5F3B-4926-AA40-9A964CB994A7Q22252886-92EEFCFD-AC3A-461D-BB56-CFA852C3C136Q22252935-12F08FD8-0AC7-4168-B3B4-9CCC99CCFA1BQ24301425-A18D99DF-771C-45F3-99D0-BF30C6C2A9DDQ24309367-B226A90B-4DFB-423A-BA30-400D4F977BDCQ24597126-4D889D2A-1C00-4B71-AA25-1770C1C0E199Q24650965-53D1581A-FD70-440A-9138-BA89F1423EB0Q24656668-2E576DDA-D423-4416-BE9E-89AC75399767Q24672819-F7CD9832-9FE8-4034-BC50-245790A0D03BQ25002311-35E8940A-A871-4069-8BAA-32A68E3551F9Q26740467-A38AC1C1-B3B3-4D89-8183-DE77F921B564Q26768732-2D576ED1-64C3-4ECB-B1D8-5CEAA88C9966Q26851112-C04534D8-2E18-479E-8803-74D5672F9007Q26995786-091DED40-1C86-4560-BA04-6678A9DB2642Q28201035-5F691AD9-AFA1-43F5-A32E-985DD2EFA03AQ28235853-BE4C8C27-FD67-43DD-A390-5585FC12F50EQ28245695-41FE07FF-FA36-4CF4-8FD7-138AB320518CQ28255862-64FA4C8C-75AF-4BDD-98F6-A6B8892B4D1FQ28257488-84F0BBDC-2D6D-4B71-A24C-3100D8752DD0Q28267025-08CDC8F6-A62F-4982-85E1-AB0844C3D372Q28279842-11B128E1-9F5D-4415-BEFF-669039112CE7Q28292055-96F61FEA-A50D-4F62-907F-7B8C09A3F386Q28292932-02DE9F7C-53D0-498D-BED6-4797A4F60280Q28300428-DFE408E2-41AF-4ECC-BBF8-52B7A3F78750Q28304886-50B1CD2F-D0F2-4FC8-A468-D31118C346A7Q28304977-7E58DC06-81C7-4960-A013-F84979ACDC4DQ28317869-7E1BE355-F131-4A05-98FC-C95BD5D643E3Q28317873-855E3045-9CA1-478A-B1D9-E8524D26E2E5Q28318103-3595B561-8F39-4C93-85B5-CC3E21C6163AQ28318174-599202AA-9497-4CE4-AAE8-4372F864FDA6Q28318197-91AA1DEB-4389-4C31-86FC-E85FE2FBFC98Q28319345-7D9CAD6A-83BF-42E7-BEE0-6CF204F2D24FQ28327209-74B9F04A-6806-4116-95C8-2070564AA272Q28332726-ED75D668-6DE6-47FD-8F19-EDCC81A3ACFAQ28360531-3A4D0B5F-D6DF-4D03-9D04-8AB51FB0E236Q28367080-1979FAEE-21D6-42E1-9B44-F50B53DE6704Q28367468-1EA39308-621D-4AD8-9B90-3E305D96DD72Q28372146-250739E2-F94B-4495-9CD3-C3211DB1E90FQ28375639-9E14EAEC-D6C2-45D7-A3B8-2E377D90FBB6Q28379097-9D1D9143-1B7F-4B59-8005-2526F57955F9
P50
description
Brits neuroloog
@nl
dokter asal Britania Raya
@id
neurologist
@en
name
Andrew John Lees
@en
Andrew Lees (neurologist)
@nl
Andrew Lees
@ast
Andrew Lees
@ca
Andrew Lees
@de
Andrew Lees
@es
Andrew Lees
@fr
Andrew Lees
@hu
Andrew Lees
@sl
type
label
Andrew John Lees
@en
Andrew Lees (neurologist)
@nl
Andrew Lees
@ast
Andrew Lees
@ca
Andrew Lees
@de
Andrew Lees
@es
Andrew Lees
@fr
Andrew Lees
@hu
Andrew Lees
@sl
altLabel
A J Lees
@en
A Lees
@en
A. J. Lees
@en
A. Lees
@en
Andrew Lees
@en
Lees A
@en
Lees A. J.
@en
Lees A.
@en
Lees AJ
@en
Lees
@en
prefLabel
Andrew John Lees
@en
Andrew Lees (neurologist)
@nl
Andrew Lees
@ast
Andrew Lees
@ca
Andrew Lees
@de
Andrew Lees
@es
Andrew Lees
@fr
Andrew Lees
@hu
Andrew Lees
@sl
P106
P1006
P214
P227
P244
P5361
P1006
P1280
P19
P21
P213
0000 0000 6676 5509
P214
P227
P244
P31
P496
0000-0002-2476-4385
P5361
LeesAndrew1947-
P569
1947-01-01T00:00:00Z
1947-09-27T00:00:00Z